CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended		94 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Costs and Expenses:
Research and development	$ 10,782	$ 8,246	$ 34,181	$ 21,210	$ 91,888
Purchased in-process research and development					29,157
General and administrative	2,692	1,843	8,773	5,493	36,358
Loss from Operations	(13,474)	(10,089)	(42,954)	(26,703)	(157,403)
Interest and investment income	14	63	48	150	544
Interest expense					(12)
Other income				256	1,363
Change in fair value of derivative instruments-warrants	(77)	140	633	(1,169)	4,254
Total Other (Expense)/Income	(63)	203	681	(763)	6,149
Loss from Continuing Operations	(13,537)	(9,886)	(42,273)	(27,466)	(151,254)
Loss from discontinued operations					(72)
Net Loss	$ (13,537)	$ (9,886)	$ (42,273)	$ (27,466)	$ (151,326)
Weighted Average Common Shares Outstanding Basic and Diluted (in shares)	90,182,115	65,806,178	83,548,398	60,194,004
Net Loss per Common Share, Basic and Diluted
Net Loss per Common Share, Basic and Diluted (in dollars per share)	$ (0.15)	$ (0.15)	$ (0.51)	$ (0.46)